Drug Delivery Technology

SoluBest has developed a proprietary nanotechnology platform (Solumer ^TM) for significantly improving the bioperformance of poorly soluble and insoluble. The versatile solubilization technology is widely applicable to numerous off-patent (or soon to be off-patent) drugs and NCEs. Rapid screening times allow the identification of suitable candidates in a few short weeks. Feasibility studies to clinical batch preparation can proceed in under 6 months. A significant advantage of the technology stems from its use of readily available equipment for a process consisting of a few simple steps, making scale-up safe, robust, rapid, and inexpensive. The company’s strategy focuses on the development of novel drug formulations that can be performed in collaboration with API manufacturers, generic and brand pharmaceutical companies, biotechs, and drug delivery firms. For more information, visit SoluBest at www.solubest.com.

Pharmaburst ^TMis the first and ONLY patented off-the-shelf co-processed excipient system for fast-dissolving ODT applications in the pharmaceutical market. It is now being used in a wide variety of new and generic drug applications by many leading multi-nationals and several top generic companies. Pharmaburst is the only ODT platform included in the USFDA’s Inactive Ingredient Guide (IIG List). Since its inception, several grades of Pharmaburst have been introduced to meet specific formulation needs. A brand new version with superior performance and cost effectiveness will be launched. Oral dispersible drugs containing Pharmaburst have been successfully launched in regulated and developing markets around the world for indications such as migraine, allergy, analgesics, anxiety, oncology, schizophrenia, depression, Parkinson's, etc. SPI Pharma has a fully integrated drug development program that utilizes its functionally superior excipients, proprietary delivery platforms, and enhanced APIs. For more information, visit SPI Pharma at www.spipharma.com.

Drug Delivery Technology June 2009 Vol 9 No 6

Xcelience is the premier source for unsurpassed quality in drug development services. The company brings together the industry's most experienced and talented scientists, consistently and efficiently moving compounds through the research and development continuum to regulatory approval. Since 1997, the Tampa-based laboratory has been developing formulations for clients throughout the pharmaceutical industry. Xcelience's unique corporate structure creates project teams that work intensively with each client, bringing an extension of their own organization into the Xcelience lab. The lab uses only state-of-the-art equipment, highlighted by the patented Xcelodose^®, which fills API directly to capsules (Xcelodose is a registered trademark of Capsugel BVBA). This and other technologies give Xcelience unparalleled speed to market without compromising its absolute commitment to quality. For more information, contact Xcelience at (608) 643-4444 or visit www.xcelience.com.

Gateway BioPharma’s solubilization platform offers a compelling approach to overcome solubility challenges, accelerate drug development, and improve patient outcomes. Our platform will advance the way a wide array of compounds are manufactured and administered to patients. At the core is a suite of novel particle engineering technologies that produce superior nanostructured particles with high surface area, providing rapid dissolution, improved physical stability, and exceptional bioavailability when compared to conventional formulation technologies. We take a portfolio approach to solving solubilization issues, based on well-characterized and scalable controlled particle growth technologies, regardless of the delivery objectives for a particular drug. Both Controlled Precipitation and Ultra-Rapid Freezing are used in order to optimize compound solubility and long-term stability. For more information, contact Gateway BioPharma at (512) 891-1216 or visit www.gatewaybio.com.